Join Growin Stock Community!

Pliant therapeutics, inc.PLRX.US Overview

US StockHealthcare
(No presentation for PLRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PLRX AI Insights

PLRX Overall Performance

PLRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PLRX Recent Performance

-1.92%

Pliant therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PLRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PLRX Key Information

PLRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PLRX Profile

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Price of PLRX

PLRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PLRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3071.82
PB Ratio
0.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3071.82
PB Ratio
0.40
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is PLRX's latest earnings report released?

    The most recent financial report for Pliant therapeutics, inc. (PLRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PLRX's short-term business performance and financial health. For the latest updates on PLRX's earnings releases, visit this page regularly.

  • How much debt does PLRX have?

    As of the end of the reporting period, Pliant therapeutics, inc. (PLRX) had total debt of 59.86M, with a debt ratio of 0.22. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PLRX have?

    At the end of the period, Pliant therapeutics, inc. (PLRX) held Total Cash and Cash Equivalents of 95.21M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PLRX's EPS continuing to grow?

    According to the past four quarterly reports, Pliant therapeutics, inc. (PLRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.43. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PLRX?

    Pliant therapeutics, inc. (PLRX)'s Free Cash Flow (FCF) for the period is -20.93M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 36.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PLRX?

    The latest valuation data shows Pliant therapeutics, inc. (PLRX) has a Price-To-Earnings (PE) ratio of -0.54 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.